PPP2R1A

And then we reported one of the patients went for another scan and had additional 10%, so minus 55% tumor shrinkage with minimal side effects.

And both had the same mutation, PPP2R1A.

And so would you take this in conjunction with, say, like chemotherapy, but just have to take less chemotherapy and less side effects because you're doing a lot of the heavy lifting? Or is this a treatment all on its own?

That exactly is the question that we're trying to address right now.

One strategy is indication independent of the mutation, and that's USC, uterus serous carcinoma, because there's so much, there's high germ instability there that we do not need to pre-selectation.

Then we have mutation independent of the indication.

That's the PPP2R1A, FBXW7, cyclin E.

Those patients that have, it can be prostate cancer, it can be breast cancer, it can be other tumor types, but they have to carry this mutation.